These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18316956)

  • 1. Glitazones and the cardiovascular system.
    Devchand PR
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):188-92. PubMed ID: 18316956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
    J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glitazones in type 2 diabetes: an update.
    Drug Ther Bull; 2008 Apr; 46(4):25-9. PubMed ID: 18403615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of glitazones in management of type 2 diabetes. A dream or a nightmare?
    Lindberg M; Astrup A
    Obes Rev; 2007 Sep; 8(5):381-4. PubMed ID: 17716295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 2 diabetes, psoriasis and thiazolidinediones.
    Krentz AJ; Friedmann PS
    Int J Clin Pract; 2006 Mar; 60(3):362-3. PubMed ID: 16494655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006.
    Casscells SW; Granger E; Swedorske J; Goldhammer R; Shaheen M; Dorris J; Hong A; Wiktor M
    Am J Ther; 2008; 15(3):198-205. PubMed ID: 18496256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
    Winkelmayer WC; Setoguchi S; Levin R; Solomon DH
    Arch Intern Med; 2008 Nov; 168(21):2368-75. PubMed ID: 19029503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glitazones and the management of insulin resistance: what they do and how might they be used.
    Einhorn D; Aroda VR; Henry RR
    Endocrinol Metab Clin North Am; 2004 Sep; 33(3):595-616, vii-viii. PubMed ID: 15262299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials.
    Charbonnel B
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():19-20. PubMed ID: 18001315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleiotropic effects of thiazolidinediones.
    Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.
    Stafylas PC; Sarafidis PA; Lasaridis AN
    Int J Cardiol; 2009 Jan; 131(3):298-304. PubMed ID: 18684530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug utilization, safety and clinical use of Actos and Avandia.
    Marks DH
    Int J Risk Saf Med; 2013 Jan; 25(1):39-51. PubMed ID: 23442297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rough road for rosiglitazone.
    Goldfine AB
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value equation for rosiglitazone and pioglitazone in older persons.
    Zarowitz BJ
    Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
    [No Abstract]   [Full Text] [Related]  

  • 20. Controversies in type 2 diabetes - An update.
    Yeap BB
    Aust Fam Physician; 2009; 38(1-2):22-5. PubMed ID: 19283231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.